Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 311

1.

Clinical outcome of recurrent locally advanced cervical cancer (LACC) submitted to primary multimodality therapies.

Legge F, Chiantera V, Macchia G, Fagotti A, Fanfani F, Ercoli A, Gallotta V, Morganti AG, Valentini V, Scambia G, Ferrandina G.

Gynecol Oncol. 2015 May 1. pii: S0090-8258(15)00864-1. doi: 10.1016/j.ygyno.2015.04.035. [Epub ahead of print]

PMID:
25940427
2.

Chemoradiation with concomitant boosts followed by radical surgery in locally advanced cervical cancer: long-term results of the ROMA-2 prospective phase 2 study.

Ferrandina G, Gambacorta A, Gallotta V, Smaniotto D, Fagotti A, Tagliaferri L, Foti E, Fanfani F, Autorino R, Scambia G, Valentini V.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):778-85. doi: 10.1016/j.ijrobp.2014.07.033. Epub 2014 Oct 18.

PMID:
25585781
3.

Management of bilateral malignant ovarian germ cell tumors: a MITO-9 retrospective study.

Sigismondi C, Scollo P, Ferrandina G, Candiani M, Angioli R, Viganò R, Scarfone G, Mangili G.

Int J Gynecol Cancer. 2015 Feb;25(2):203-7. doi: 10.1097/IGC.0000000000000358.

PMID:
25569816
4.

Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary?

Ottolina J, Ferrandina G, Gadducci A, Scollo P, Lorusso D, Giorda G, Breda E, Savarese A, Candiani M, Zullo F, Mangili G.

Gynecol Oncol. 2015 Feb;136(2):230-4. doi: 10.1016/j.ygyno.2014.12.016. Epub 2014 Dec 17.

PMID:
25527364
5.

Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study.

Ferrandina G, Corrado G, Mascilini F, Malaguti P, Samaritani R, Distefano M, Masciullo V, Di Legge A, Savarese A, Scambia G.

BMC Cancer. 2014 Dec 13;14:947. doi: 10.1186/1471-2407-14-947.

6.

Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy.

Bosetti R, Ferrandina G, Marneffe W, Scambia G, Vereeck L.

Nanomedicine (Lond). 2014 Jul;9(14):2175-86. doi: 10.2217/nnm.14.150.

PMID:
25405795
7.

Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy.

Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG, Bagnato A.

Cancer Res. 2014 Dec 15;74(24):7453-64. doi: 10.1158/0008-5472.CAN-13-3133. Epub 2014 Nov 6.

PMID:
25377471
8.

Laparoscopic staging of apparent early stage ovarian cancer: results of a large, retrospective, multi-institutional series.

Gallotta V, Ghezzi F, Vizza E, Chiantera V, Ceccaroni M, Franchi M, Fagotti A, Ercoli A, Fanfani F, Parrino C, Uccella S, Corrado G, Scambia G, Ferrandina G.

Gynecol Oncol. 2014 Dec;135(3):428-34. doi: 10.1016/j.ygyno.2014.09.006. Epub 2014 Sep 16.

PMID:
25230214
9.

Combining targeted therapies in ovarian cancer.

Scambia G, Salutari V, Ferrandina G.

Lancet Oncol. 2014 Oct;15(11):1179-81. doi: 10.1016/S1470-2045(14)70421-8. Epub 2014 Sep 10. No abstract available.

PMID:
25218905
10.

Volumetric intensity modulated arc therapy for stereotactic body radiosurgery in oligometastatic breast and gynecological cancers: feasibility and clinical results.

Macchia G, Deodato F, Cilla S, Torre G, Corrado G, Legge F, Gambacorta MA, Tagliaferri L, Mignogna S, Scambia G, Valentini V, Morganti AG, Ferrandina G.

Oncol Rep. 2014 Nov;32(5):2237-43. doi: 10.3892/or.2014.3412. Epub 2014 Aug 18.

PMID:
25175950
11.

Stereotactic radiosurgery (SRS) with volumetric modulated arc therapy (VMAT): interim results of a multi-arm phase I trial (DESTROY-2).

Deodato F, Cilla S, Macchia G, Torre G, Caravatta L, Mariano G, Mignogna S, Ferro M, Mattiucci GC, Balducci M, Frascino V, Piermattei A, Ferrandina G, Valentini V, Morganti AG.

Clin Oncol (R Coll Radiol). 2014 Dec;26(12):748-56. doi: 10.1016/j.clon.2014.08.005. Epub 2014 Aug 29.

PMID:
25175042
12.

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.

Mascilini F, Amadio G, Di Stefano MG, Ludovisi M, Di Legge A, Conte C, De Vincenzo R, Ricci C, Masciullo V, Salutari V, Scambia G, Ferrandina G.

Onco Targets Ther. 2014 Jul 12;7:1273-84. doi: 10.2147/OTT.S51550. eCollection 2014. Review.

13.

Survivin protein as predictor of pathologic response in patients with locally advanced cervical cancer treated with chemoradiation followed by radical surgery.

Zannoni GF, Petrillo M, Vellone VG, Martinelli E, Chiarello G, Ferrandina G, Scambia G.

Hum Pathol. 2014 Sep;45(9):1872-8. doi: 10.1016/j.humpath.2014.03.022. Epub 2014 May 27.

PMID:
24997647
14.

Evaluation of quality of life and emotional distress in endometrial cancer patients: a 2-year prospective, longitudinal study.

Ferrandina G, Petrillo M, Mantegna G, Fuoco G, Terzano S, Venditti L, Marcellusi A, De Vincenzo R, Scambia G.

Gynecol Oncol. 2014 Jun;133(3):518-25. doi: 10.1016/j.ygyno.2014.03.015. Epub 2014 Mar 14.

PMID:
24637198
15.

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators.

Lancet Oncol. 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28.

PMID:
24582486
16.

Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: prognostic role and clinical considerations.

Gallotta V, Fanfani F, Fagotti A, Chiantera V, Legge F, Gueli Alletti S, Nero C, Margariti AP, Papa V, Alfieri S, Ciccarone F, Scambia G, Ferrandina G.

Ann Surg Oncol. 2014 Jul;21(7):2369-75. doi: 10.1245/s10434-014-3558-0. Epub 2014 Feb 21.

PMID:
24558070
17.

Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients.

Chiantera V, Rossi M, De Iaco P, Koehler C, Marnitz S, Ferrandina G, Legge F, Parazzini F, Scambia G, Schneider A, Vercellino GF.

Int J Gynecol Cancer. 2014 Jun;24(5):916-22. doi: 10.1097/IGC.0b013e3182a80aec.

PMID:
24442006
18.

Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience.

Gallotta V, Fagotti A, Fanfani F, Ferrandina G, Nero C, Costantini B, Gueli Alletti S, Chiantera V, Ercoli A, Scambia G.

Surg Endosc. 2014 Jun;28(6):1808-15. doi: 10.1007/s00464-013-3390-9. Epub 2014 Jan 11.

PMID:
24414460
19.

Completion surgery after concomitant chemoradiation in locally advanced cervical cancer: a comprehensive analysis of pattern of postoperative complications.

Ferrandina G, Ercoli A, Fagotti A, Fanfani F, Gallotta V, Margariti AP, Salerno MG, Chiantera V, Legge F, Macchia G, Morganti AG, Valentini V, Scambia G.

Ann Surg Oncol. 2014 May;21(5):1692-9. doi: 10.1245/s10434-013-3471-y. Epub 2014 Jan 10.

PMID:
24407316
20.

Successful treatment of a young patient with locally advanced clear cell adenocarcinoma of the uterine cervix undergoing chemoradiation followed by radical surgery.

Ferrandina G, Lucidi A, De Ninno M, Carbone A, Chiantera V, Morganti AG, Macchia G.

Gynecol Obstet Invest. 2014;77(1):64-7. doi: 10.1159/000356685. Epub 2013 Nov 27.

PMID:
24296792
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk